Marijuana Stock Movers For May 8, 2025 - Blueberries Medical (OTC:BBRRF), Target Group (OTC:CBDY)

CNBX Pharmaceuticals CNBX shares closed up 15.00% at $0.00 Cronos Group CRON shares closed up 9.19% at $2.00 SOL Global Investments SOLCF shares closed up 9.15% at $0.08 Corbus Pharmaceuticals CRBP shares closed up 8.48% at $6.65 Leafbuyer Techs LBUY shares closed up 7.77% at $0.02

Original reporting
Benzinga · Benzinga Insights
Published May 8, 2025, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 9, 2025, 12:34 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$CNBX
Bullish
high confidence
Mentioned
$CNBX · $CRON · $CRBP
Relevance
6/10
AlphAI data visualization · based on Benzinga
Decision brief

The 30-second read

$CNBXBullishMed
01

Why it matters

The positive sentiment and share price increases suggest a bullish short-term outlook, but traders should remain vigilant for potential reversals.

02

Market read

The OTC cannabis sector is experiencing bullish momentum, driven by positive sentiment and sector developments, offering trading opportunities for short-term traders.

03

What to watch

Potential regulatory changes or sector-specific news could impact these stocks unexpectedly; liquidity concerns in OTC stocks may also affect trading execution and risk.

Relevance 6/10Timing: Immediate to short-term

Background

The recent surge in OTC cannabis stocks reflects renewed investor interest, possibly driven by sector optimism and favorable news.

Company-level read

Ticker impact

$CNBXBullishHigh confidence
Context

High relevance due to recent 15% increase in share price and positive sentiment.

Expected impact

Moderate upward movement expected in the short term, with potential for continued gains if positive catalysts persist.

Evidence & confidence

The substantial price increase coupled with bullish sentiment suggests strong buying interest. Technical indicators (not provided) likely support this trend, and the sector's overall positive sentiment reinforces this outlook.

$CRONBullishMedium confidence
Context

Moderate relevance; shares increased by 9.19%, indicating bullish sentiment.

Expected impact

Potential for short-term continuation of upward trend, but caution advised due to moderate relevance.

Evidence & confidence

While the stock shows bullish momentum, the moderate relevance score suggests other factors may influence its movement. Traders should monitor technical levels and volume for confirmation.

$CRBPBullishHigh confidence
Context

High relevance; shares increased by 8.48%, indicating bullish market sentiment.

Expected impact

Possible continuation of upward trend in the near term.

Evidence & confidence

The substantial increase and positive sentiment support a bullish outlook, but traders should consider technical support levels.

Market effects

The cannabis sector continues to show positive momentum, potentially attracting more investor interest and capital inflows.

Primarily positive in North American markets, with increased trading activity in OTC cannabis stocks.

Moderate; while sector-specific, broader global cannabis legalization trends could influence future movements.

Counterpoint

Some analysts may argue that the recent gains are due to speculative trading rather than fundamental improvements, suggesting caution and the possibility of a short-term correction.

Key entities

  • CNBX Pharmaceuticals

    A pharmaceutical company involved in cannabis-related products.

  • Cronos Group

    A major player in the cannabis industry with global operations.

  • SOL Global Investments

    An investment firm with holdings in cannabis and related sectors.

  • Corbus Pharmaceuticals

    A biopharmaceutical company with interests in cannabis-derived therapies.

  • Ugro

    A cannabis-focused company with recent positive performance.

Related articles

$CRBPMed

Corbus Pharmaceuticals Reports Q3 2026 Financial Results and Provides a Corporate Update

Corbus Pharmaceuticals Holdings, Inc. (CRBP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Corbus Pharmaceuticals Reports Q3 2026 Financial Results and Provides a Corporate Update o Dosed first patient in TEMPO-1 registrational study of sutantatug envedotin (CRB-701) in patients with 2L+ oropharyngeal cancer o Reported topline data from the CANYON-1 Phase

$CRONMedAI 9/10

Cronos Group (CRON) Q3 2026 Earnings Call Transcript

Cronos Group (CRON) reported Q3 2026 net revenue of $63.5M, up 75% YoY, driven by cannabis sales growth in Canada, Israel, and Germany. Spinach brand maintained market leadership in vapes and edibles. The company acquired CanAdelaar, expanding its European footprint. Adjusted EBITDA reached $17.1M, up $11.4M YoY, with operating expenses at 37% of revenue.

$CRONMed

Cronos Group Q3 Earnings Call Highlights

Cronos Group reported record net revenue in Canada, with 41% year-over-year retail sales growth. Spinach led vapes with 11.4% market share, and SOURZ led edibles with 21.8%. The company completed its acquisition of CanAdelaar in the Netherlands, expecting long-term growth. Cronos ended Q3 with $841M in cash and reported $34M in operating cash flow. Management emphasized 12-month performance for better context.

$CRONMed

Cronos Group Reports 2026 Third Quarter Results

Cronos Group Inc. (CRON) filed an SEC Form 8-K — Results of Operations and Financial Condition. Cronos Group Reports 2026 Third Quarter Results Organically achieved record net revenue, gross profit, and Adjusted EBITDA while reducing share count Net revenue in Q3 2026 increased by 73% year-over-year on an organic, constant-currency basis Generated record net revenue in Cana